Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.
Identifieur interne : 003253 ( PubMed/Checkpoint ); précédent : 003252; suivant : 003254Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.
Auteurs : Thomas E. Hutson [États-Unis] ; Bernard Escudier ; Emilio Esteban ; Georg A. Bjarnason ; Ho Yeong Lim ; Kenneth B. Pittman ; Peggy Senico ; Andreas Niethammer ; Dongrui Ray Lu ; Subramanian Hariharan ; Robert J. MotzerSource :
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology [ 1527-7755 ] ; 2014.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Estimation de Kaplan-Meier, Facteurs temps, Femelle, Humains, Indoles (usage thérapeutique), Inhibiteurs de l'angiogenèse (effets indésirables), Inhibiteurs de l'angiogenèse (usage thérapeutique), Inhibiteurs de protéines kinases (effets indésirables), Inhibiteurs de protéines kinases (usage thérapeutique), Jeune adulte, Mâle, Nicotinamide (analogues et dérivés), Nicotinamide (effets indésirables), Nicotinamide (usage thérapeutique), Néphrocarcinome (enzymologie), Néphrocarcinome (mortalité), Néphrocarcinome (secondaire), Néphrocarcinome (traitement médicamenteux), Phénylurées (effets indésirables), Phénylurées (usage thérapeutique), Pyrroles (usage thérapeutique), Récepteurs aux facteurs de croissance endothéliale vasculaire (antagonistes et inhibiteurs), Récepteurs aux facteurs de croissance endothéliale vasculaire (métabolisme), Sirolimus (analogues et dérivés), Sirolimus (effets indésirables), Sirolimus (usage thérapeutique), Sujet âgé, Sujet âgé de 80 ans ou plus, Survie sans rechute, Sérine-thréonine kinases TOR (antagonistes et inhibiteurs), Sérine-thréonine kinases TOR (métabolisme), Thérapie moléculaire ciblée, Tumeurs du rein (anatomopathologie), Tumeurs du rein (enzymologie), Tumeurs du rein (mortalité), Tumeurs du rein (traitement médicamenteux), Échec thérapeutique, Évolution de la maladie.
- MESH :
- analogues et dérivés : Nicotinamide, Sirolimus.
- anatomopathologie : Tumeurs du rein.
- antagonistes et inhibiteurs : Récepteurs aux facteurs de croissance endothéliale vasculaire, Sérine-thréonine kinases TOR.
- effets indésirables : Inhibiteurs de l'angiogenèse, Inhibiteurs de protéines kinases, Nicotinamide, Phénylurées, Sirolimus.
- enzymologie : Néphrocarcinome, Tumeurs du rein.
- mortalité : Néphrocarcinome, Tumeurs du rein.
- métabolisme : Récepteurs aux facteurs de croissance endothéliale vasculaire, Sérine-thréonine kinases TOR.
- secondaire : Néphrocarcinome.
- traitement médicamenteux : Néphrocarcinome, Tumeurs du rein.
- usage thérapeutique : Indoles, Inhibiteurs de l'angiogenèse, Inhibiteurs de protéines kinases, Nicotinamide, Phénylurées, Pyrroles, Sirolimus.
- Adulte, Adulte d'âge moyen, Estimation de Kaplan-Meier, Facteurs temps, Femelle, Humains, Jeune adulte, Mâle, Sujet âgé, Sujet âgé de 80 ans ou plus, Survie sans rechute, Thérapie moléculaire ciblée, Échec thérapeutique, Évolution de la maladie.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Angiogenesis Inhibitors (adverse effects), Angiogenesis Inhibitors (therapeutic use), Carcinoma, Renal Cell (drug therapy), Carcinoma, Renal Cell (enzymology), Carcinoma, Renal Cell (mortality), Carcinoma, Renal Cell (secondary), Disease Progression, Disease-Free Survival, Female, Humans, Indoles (therapeutic use), Kaplan-Meier Estimate, Kidney Neoplasms (drug therapy), Kidney Neoplasms (enzymology), Kidney Neoplasms (mortality), Kidney Neoplasms (pathology), Male, Middle Aged, Molecular Targeted Therapy, Niacinamide (adverse effects), Niacinamide (analogs & derivatives), Niacinamide (therapeutic use), Phenylurea Compounds (adverse effects), Phenylurea Compounds (therapeutic use), Protein Kinase Inhibitors (adverse effects), Protein Kinase Inhibitors (therapeutic use), Pyrroles (therapeutic use), Receptors, Vascular Endothelial Growth Factor (antagonists & inhibitors), Receptors, Vascular Endothelial Growth Factor (metabolism), Sirolimus (adverse effects), Sirolimus (analogs & derivatives), Sirolimus (therapeutic use), TOR Serine-Threonine Kinases (antagonists & inhibitors), TOR Serine-Threonine Kinases (metabolism), Time Factors, Treatment Failure, Young Adult.
- MESH :
- chemical , adverse effects : Angiogenesis Inhibitors, Niacinamide, Phenylurea Compounds, Protein Kinase Inhibitors, Sirolimus.
- chemical , analogs & derivatives : Niacinamide, Sirolimus.
- chemical , antagonists & inhibitors : Receptors, Vascular Endothelial Growth Factor, TOR Serine-Threonine Kinases.
- chemical , metabolism : Receptors, Vascular Endothelial Growth Factor, TOR Serine-Threonine Kinases.
- chemical , therapeutic use : Angiogenesis Inhibitors, Indoles, Niacinamide, Phenylurea Compounds, Protein Kinase Inhibitors, Pyrroles, Sirolimus.
- drug therapy : Carcinoma, Renal Cell, Kidney Neoplasms.
- enzymology : Carcinoma, Renal Cell, Kidney Neoplasms.
- mortality : Carcinoma, Renal Cell, Kidney Neoplasms.
- pathology : Kidney Neoplasms.
- secondary : Carcinoma, Renal Cell.
- Adult, Aged, Aged, 80 and over, Disease Progression, Disease-Free Survival, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Molecular Targeted Therapy, Time Factors, Treatment Failure, Young Adult.
Abstract
This international phase III trial (Investigating Torisel As Second-Line Therapy [INTORSECT]) compared the efficacy of temsirolimus (mammalian target of rapamycin inhibitor) and sorafenib (vascular endothelial growth factor receptor [VEGFR] tyrosine kinase inhibitor) as second-line therapy in patients with metastatic renal cell carcinoma (mRCC) after disease progression on sunitinib.
DOI: 10.1200/JCO.2013.50.3961
PubMed: 24297950
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:24297950Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.</title>
<author><name sortKey="Hutson, Thomas E" sort="Hutson, Thomas E" uniqKey="Hutson T" first="Thomas E" last="Hutson">Thomas E. Hutson</name>
<affiliation wicri:level="2"><nlm:affiliation>Thomas E. Hutson, Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, TX; Bernard Escudier, Institut Gustave Roussy, Villejuif, France; Emilio Esteban, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain; Georg A. Bjarnason, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Ho Yeong Lim, Samsung Medical Center, Seoul, Korea; Kenneth B. Pittman, The Queen Elizabeth Hospital, Woodville South, Adelaide, Australia; Peggy Senico, Pfizer, Collegeville, PA; Andreas Niethammer and Dongrui Ray Lu Pfizer, La Jolla, CA; Subramanian Hariharan, Pfizer; and Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Thomas E. Hutson, Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, TX; Bernard Escudier, Institut Gustave Roussy, Villejuif, France; Emilio Esteban, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain; Georg A. Bjarnason, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Ho Yeong Lim, Samsung Medical Center, Seoul, Korea; Kenneth B. Pittman, The Queen Elizabeth Hospital, Woodville South, Adelaide, Australia; Peggy Senico, Pfizer, Collegeville, PA; Andreas Niethammer and Dongrui Ray Lu Pfizer, La Jolla, CA; Subramanian Hariharan, Pfizer; and Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Escudier, Bernard" sort="Escudier, Bernard" uniqKey="Escudier B" first="Bernard" last="Escudier">Bernard Escudier</name>
</author>
<author><name sortKey="Esteban, Emilio" sort="Esteban, Emilio" uniqKey="Esteban E" first="Emilio" last="Esteban">Emilio Esteban</name>
</author>
<author><name sortKey="Bjarnason, Georg A" sort="Bjarnason, Georg A" uniqKey="Bjarnason G" first="Georg A" last="Bjarnason">Georg A. Bjarnason</name>
</author>
<author><name sortKey="Lim, Ho Yeong" sort="Lim, Ho Yeong" uniqKey="Lim H" first="Ho Yeong" last="Lim">Ho Yeong Lim</name>
</author>
<author><name sortKey="Pittman, Kenneth B" sort="Pittman, Kenneth B" uniqKey="Pittman K" first="Kenneth B" last="Pittman">Kenneth B. Pittman</name>
</author>
<author><name sortKey="Senico, Peggy" sort="Senico, Peggy" uniqKey="Senico P" first="Peggy" last="Senico">Peggy Senico</name>
</author>
<author><name sortKey="Niethammer, Andreas" sort="Niethammer, Andreas" uniqKey="Niethammer A" first="Andreas" last="Niethammer">Andreas Niethammer</name>
</author>
<author><name sortKey="Lu, Dongrui Ray" sort="Lu, Dongrui Ray" uniqKey="Lu D" first="Dongrui Ray" last="Lu">Dongrui Ray Lu</name>
</author>
<author><name sortKey="Hariharan, Subramanian" sort="Hariharan, Subramanian" uniqKey="Hariharan S" first="Subramanian" last="Hariharan">Subramanian Hariharan</name>
</author>
<author><name sortKey="Motzer, Robert J" sort="Motzer, Robert J" uniqKey="Motzer R" first="Robert J" last="Motzer">Robert J. Motzer</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:24297950</idno>
<idno type="pmid">24297950</idno>
<idno type="doi">10.1200/JCO.2013.50.3961</idno>
<idno type="wicri:Area/PubMed/Corpus">003896</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003896</idno>
<idno type="wicri:Area/PubMed/Curation">003781</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003781</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003781</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003781</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.</title>
<author><name sortKey="Hutson, Thomas E" sort="Hutson, Thomas E" uniqKey="Hutson T" first="Thomas E" last="Hutson">Thomas E. Hutson</name>
<affiliation wicri:level="2"><nlm:affiliation>Thomas E. Hutson, Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, TX; Bernard Escudier, Institut Gustave Roussy, Villejuif, France; Emilio Esteban, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain; Georg A. Bjarnason, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Ho Yeong Lim, Samsung Medical Center, Seoul, Korea; Kenneth B. Pittman, The Queen Elizabeth Hospital, Woodville South, Adelaide, Australia; Peggy Senico, Pfizer, Collegeville, PA; Andreas Niethammer and Dongrui Ray Lu Pfizer, La Jolla, CA; Subramanian Hariharan, Pfizer; and Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Thomas E. Hutson, Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, TX; Bernard Escudier, Institut Gustave Roussy, Villejuif, France; Emilio Esteban, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain; Georg A. Bjarnason, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Ho Yeong Lim, Samsung Medical Center, Seoul, Korea; Kenneth B. Pittman, The Queen Elizabeth Hospital, Woodville South, Adelaide, Australia; Peggy Senico, Pfizer, Collegeville, PA; Andreas Niethammer and Dongrui Ray Lu Pfizer, La Jolla, CA; Subramanian Hariharan, Pfizer; and Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Escudier, Bernard" sort="Escudier, Bernard" uniqKey="Escudier B" first="Bernard" last="Escudier">Bernard Escudier</name>
</author>
<author><name sortKey="Esteban, Emilio" sort="Esteban, Emilio" uniqKey="Esteban E" first="Emilio" last="Esteban">Emilio Esteban</name>
</author>
<author><name sortKey="Bjarnason, Georg A" sort="Bjarnason, Georg A" uniqKey="Bjarnason G" first="Georg A" last="Bjarnason">Georg A. Bjarnason</name>
</author>
<author><name sortKey="Lim, Ho Yeong" sort="Lim, Ho Yeong" uniqKey="Lim H" first="Ho Yeong" last="Lim">Ho Yeong Lim</name>
</author>
<author><name sortKey="Pittman, Kenneth B" sort="Pittman, Kenneth B" uniqKey="Pittman K" first="Kenneth B" last="Pittman">Kenneth B. Pittman</name>
</author>
<author><name sortKey="Senico, Peggy" sort="Senico, Peggy" uniqKey="Senico P" first="Peggy" last="Senico">Peggy Senico</name>
</author>
<author><name sortKey="Niethammer, Andreas" sort="Niethammer, Andreas" uniqKey="Niethammer A" first="Andreas" last="Niethammer">Andreas Niethammer</name>
</author>
<author><name sortKey="Lu, Dongrui Ray" sort="Lu, Dongrui Ray" uniqKey="Lu D" first="Dongrui Ray" last="Lu">Dongrui Ray Lu</name>
</author>
<author><name sortKey="Hariharan, Subramanian" sort="Hariharan, Subramanian" uniqKey="Hariharan S" first="Subramanian" last="Hariharan">Subramanian Hariharan</name>
</author>
<author><name sortKey="Motzer, Robert J" sort="Motzer, Robert J" uniqKey="Motzer R" first="Robert J" last="Motzer">Robert J. Motzer</name>
</author>
</analytic>
<series><title level="j">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</title>
<idno type="eISSN">1527-7755</idno>
<imprint><date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Angiogenesis Inhibitors (adverse effects)</term>
<term>Angiogenesis Inhibitors (therapeutic use)</term>
<term>Carcinoma, Renal Cell (drug therapy)</term>
<term>Carcinoma, Renal Cell (enzymology)</term>
<term>Carcinoma, Renal Cell (mortality)</term>
<term>Carcinoma, Renal Cell (secondary)</term>
<term>Disease Progression</term>
<term>Disease-Free Survival</term>
<term>Female</term>
<term>Humans</term>
<term>Indoles (therapeutic use)</term>
<term>Kaplan-Meier Estimate</term>
<term>Kidney Neoplasms (drug therapy)</term>
<term>Kidney Neoplasms (enzymology)</term>
<term>Kidney Neoplasms (mortality)</term>
<term>Kidney Neoplasms (pathology)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Molecular Targeted Therapy</term>
<term>Niacinamide (adverse effects)</term>
<term>Niacinamide (analogs & derivatives)</term>
<term>Niacinamide (therapeutic use)</term>
<term>Phenylurea Compounds (adverse effects)</term>
<term>Phenylurea Compounds (therapeutic use)</term>
<term>Protein Kinase Inhibitors (adverse effects)</term>
<term>Protein Kinase Inhibitors (therapeutic use)</term>
<term>Pyrroles (therapeutic use)</term>
<term>Receptors, Vascular Endothelial Growth Factor (antagonists & inhibitors)</term>
<term>Receptors, Vascular Endothelial Growth Factor (metabolism)</term>
<term>Sirolimus (adverse effects)</term>
<term>Sirolimus (analogs & derivatives)</term>
<term>Sirolimus (therapeutic use)</term>
<term>TOR Serine-Threonine Kinases (antagonists & inhibitors)</term>
<term>TOR Serine-Threonine Kinases (metabolism)</term>
<term>Time Factors</term>
<term>Treatment Failure</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Estimation de Kaplan-Meier</term>
<term>Facteurs temps</term>
<term>Femelle</term>
<term>Humains</term>
<term>Indoles (usage thérapeutique)</term>
<term>Inhibiteurs de l'angiogenèse (effets indésirables)</term>
<term>Inhibiteurs de l'angiogenèse (usage thérapeutique)</term>
<term>Inhibiteurs de protéines kinases (effets indésirables)</term>
<term>Inhibiteurs de protéines kinases (usage thérapeutique)</term>
<term>Jeune adulte</term>
<term>Mâle</term>
<term>Nicotinamide (analogues et dérivés)</term>
<term>Nicotinamide (effets indésirables)</term>
<term>Nicotinamide (usage thérapeutique)</term>
<term>Néphrocarcinome (enzymologie)</term>
<term>Néphrocarcinome (mortalité)</term>
<term>Néphrocarcinome (secondaire)</term>
<term>Néphrocarcinome (traitement médicamenteux)</term>
<term>Phénylurées (effets indésirables)</term>
<term>Phénylurées (usage thérapeutique)</term>
<term>Pyrroles (usage thérapeutique)</term>
<term>Récepteurs aux facteurs de croissance endothéliale vasculaire (antagonistes et inhibiteurs)</term>
<term>Récepteurs aux facteurs de croissance endothéliale vasculaire (métabolisme)</term>
<term>Sirolimus (analogues et dérivés)</term>
<term>Sirolimus (effets indésirables)</term>
<term>Sirolimus (usage thérapeutique)</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Survie sans rechute</term>
<term>Sérine-thréonine kinases TOR (antagonistes et inhibiteurs)</term>
<term>Sérine-thréonine kinases TOR (métabolisme)</term>
<term>Thérapie moléculaire ciblée</term>
<term>Tumeurs du rein (anatomopathologie)</term>
<term>Tumeurs du rein (enzymologie)</term>
<term>Tumeurs du rein (mortalité)</term>
<term>Tumeurs du rein (traitement médicamenteux)</term>
<term>Échec thérapeutique</term>
<term>Évolution de la maladie</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Angiogenesis Inhibitors</term>
<term>Niacinamide</term>
<term>Phenylurea Compounds</term>
<term>Protein Kinase Inhibitors</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Niacinamide</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Receptors, Vascular Endothelial Growth Factor</term>
<term>TOR Serine-Threonine Kinases</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Receptors, Vascular Endothelial Growth Factor</term>
<term>TOR Serine-Threonine Kinases</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Angiogenesis Inhibitors</term>
<term>Indoles</term>
<term>Niacinamide</term>
<term>Phenylurea Compounds</term>
<term>Protein Kinase Inhibitors</term>
<term>Pyrroles</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Nicotinamide</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Tumeurs du rein</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Récepteurs aux facteurs de croissance endothéliale vasculaire</term>
<term>Sérine-thréonine kinases TOR</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Carcinoma, Renal Cell</term>
<term>Kidney Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Inhibiteurs de l'angiogenèse</term>
<term>Inhibiteurs de protéines kinases</term>
<term>Nicotinamide</term>
<term>Phénylurées</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" qualifier="enzymologie" xml:lang="fr"><term>Néphrocarcinome</term>
<term>Tumeurs du rein</term>
</keywords>
<keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>Carcinoma, Renal Cell</term>
<term>Kidney Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Carcinoma, Renal Cell</term>
<term>Kidney Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Néphrocarcinome</term>
<term>Tumeurs du rein</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Récepteurs aux facteurs de croissance endothéliale vasculaire</term>
<term>Sérine-thréonine kinases TOR</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Kidney Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="secondaire" xml:lang="fr"><term>Néphrocarcinome</term>
</keywords>
<keywords scheme="MESH" qualifier="secondary" xml:lang="en"><term>Carcinoma, Renal Cell</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Néphrocarcinome</term>
<term>Tumeurs du rein</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Indoles</term>
<term>Inhibiteurs de l'angiogenèse</term>
<term>Inhibiteurs de protéines kinases</term>
<term>Nicotinamide</term>
<term>Phénylurées</term>
<term>Pyrroles</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Disease Progression</term>
<term>Disease-Free Survival</term>
<term>Female</term>
<term>Humans</term>
<term>Kaplan-Meier Estimate</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Molecular Targeted Therapy</term>
<term>Time Factors</term>
<term>Treatment Failure</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Estimation de Kaplan-Meier</term>
<term>Facteurs temps</term>
<term>Femelle</term>
<term>Humains</term>
<term>Jeune adulte</term>
<term>Mâle</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Survie sans rechute</term>
<term>Thérapie moléculaire ciblée</term>
<term>Échec thérapeutique</term>
<term>Évolution de la maladie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">This international phase III trial (Investigating Torisel As Second-Line Therapy [INTORSECT]) compared the efficacy of temsirolimus (mammalian target of rapamycin inhibitor) and sorafenib (vascular endothelial growth factor receptor [VEGFR] tyrosine kinase inhibitor) as second-line therapy in patients with metastatic renal cell carcinoma (mRCC) after disease progression on sunitinib.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24297950</PMID>
<DateCreated><Year>2014</Year>
<Month>03</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted><Year>2014</Year>
<Month>05</Month>
<Day>02</Day>
</DateCompleted>
<DateRevised><Year>2017</Year>
<Month>09</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1527-7755</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>32</Volume>
<Issue>8</Issue>
<PubDate><Year>2014</Year>
<Month>Mar</Month>
<Day>10</Day>
</PubDate>
</JournalIssue>
<Title>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</Title>
<ISOAbbreviation>J. Clin. Oncol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.</ArticleTitle>
<Pagination><MedlinePgn>760-7</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1200/JCO.2013.50.3961</ELocationID>
<Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">This international phase III trial (Investigating Torisel As Second-Line Therapy [INTORSECT]) compared the efficacy of temsirolimus (mammalian target of rapamycin inhibitor) and sorafenib (vascular endothelial growth factor receptor [VEGFR] tyrosine kinase inhibitor) as second-line therapy in patients with metastatic renal cell carcinoma (mRCC) after disease progression on sunitinib.</AbstractText>
<AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">In total, 512 patients were randomly assigned 1:1 to receive intravenous temsirolimus 25 mg once weekly (n = 259) or oral sorafenib 400 mg twice per day (n = 253), with stratification according to duration of prior sunitinib therapy (≤ or > 180 days), prognostic risk, histology (clear cell or non-clear cell), and nephrectomy status. The primary end point was progression-free survival (PFS) by independent review committee assessment. Safety, objective response rate (ORR), and overall survival (OS) were secondary end points.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Primary analysis revealed no significant difference between treatment arms for PFS (stratified hazard ratio [HR], 0.87; 95% CI, 0.71 to 1.07; two-sided P = .19) or ORR. Median PFS in the temsirolimus and sorafenib arms were 4.3 and 3.9 months, respectively. There was a significant OS difference in favor of sorafenib (stratified HR, 1.31; 95% CI, 1.05 to 1.63; two-sided P = .01). Median OS in the temsirolimus and sorafenib arms was 12.3 and 16.6 months, respectively. Safety profiles of both agents were consistent with previous studies.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In patients with mRCC and progression on sunitinib, second-line temsirolimus did not demonstrate a PFS advantage compared with sorafenib. The longer OS observed with sorafenib suggests sequenced VEGFR inhibition may benefit patients with mRCC.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hutson</LastName>
<ForeName>Thomas E</ForeName>
<Initials>TE</Initials>
<AffiliationInfo><Affiliation>Thomas E. Hutson, Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, TX; Bernard Escudier, Institut Gustave Roussy, Villejuif, France; Emilio Esteban, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain; Georg A. Bjarnason, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Ho Yeong Lim, Samsung Medical Center, Seoul, Korea; Kenneth B. Pittman, The Queen Elizabeth Hospital, Woodville South, Adelaide, Australia; Peggy Senico, Pfizer, Collegeville, PA; Andreas Niethammer and Dongrui Ray Lu Pfizer, La Jolla, CA; Subramanian Hariharan, Pfizer; and Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Escudier</LastName>
<ForeName>Bernard</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y"><LastName>Esteban</LastName>
<ForeName>Emilio</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y"><LastName>Bjarnason</LastName>
<ForeName>Georg A</ForeName>
<Initials>GA</Initials>
</Author>
<Author ValidYN="Y"><LastName>Lim</LastName>
<ForeName>Ho Yeong</ForeName>
<Initials>HY</Initials>
</Author>
<Author ValidYN="Y"><LastName>Pittman</LastName>
<ForeName>Kenneth B</ForeName>
<Initials>KB</Initials>
</Author>
<Author ValidYN="Y"><LastName>Senico</LastName>
<ForeName>Peggy</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y"><LastName>Niethammer</LastName>
<ForeName>Andreas</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y"><LastName>Lu</LastName>
<ForeName>Dongrui Ray</ForeName>
<Initials>DR</Initials>
</Author>
<Author ValidYN="Y"><LastName>Hariharan</LastName>
<ForeName>Subramanian</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Motzer</LastName>
<ForeName>Robert J</ForeName>
<Initials>RJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName>
<AccessionNumberList><AccessionNumber>NCT00474766</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<GrantList CompleteYN="Y"><Grant><GrantID>P30 CA008748</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
<PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016448">Multicenter Study</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2013</Year>
<Month>12</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>J Clin Oncol</MedlineTA>
<NlmUniqueID>8309333</NlmUniqueID>
<ISSNLinking>0732-183X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020533">Angiogenesis Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007211">Indoles</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010671">Phenylurea Compounds</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011758">Pyrroles</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>25X51I8RD4</RegistryNumber>
<NameOfSubstance UI="D009536">Niacinamide</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>624KN6GM2T</RegistryNumber>
<NameOfSubstance UI="C401859">temsirolimus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>9ZOQ3TZI87</RegistryNumber>
<NameOfSubstance UI="C471405">sorafenib</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D040262">Receptors, Vascular Endothelial Growth Factor</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>V99T50803M</RegistryNumber>
<NameOfSubstance UI="C473478">sunitinib</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>W36ZG6FT64</RegistryNumber>
<NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Clin Oncol. 2014 Feb;11(2):64</RefSource>
<PMID Version="1">24343669</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Urol. 2014 Jan;11(1):2</RefSource>
<PMID Version="1">24346004</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn"><RefSource>J Clin Oncol. 2014 Mar 10;32(8):722-4</RefSource>
<PMID Version="1">24516015</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16</RefSource>
<PMID Version="1">10655437</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2007 Jan 11;356(2):115-24</RefSource>
<PMID Version="1">17215529</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Crit Rev Oncol Hematol. 2011 Jan;77(1):48-62</RefSource>
<PMID Version="1">20705477</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2013 Oct 20;31(30):3791-9</RefSource>
<PMID Version="1">24019545</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2009 Sep 20;27(27):4469-74</RefSource>
<PMID Version="1">19652053</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2012 Jun;23 (6):1549-55</RefSource>
<PMID Version="1">22056973</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2007 Jan 11;356(2):125-34</RefSource>
<PMID Version="1">17215530</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst. 2012 Jan 18;104(2):93-113</RefSource>
<PMID Version="1">22235142</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer. 2010 Sep 15;116(18):4256-65</RefSource>
<PMID Version="1">20549832</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2007 May 31;356(22):2271-81</RefSource>
<PMID Version="1">17538086</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2011 Dec 3;378(9807):1931-9</RefSource>
<PMID Version="1">22056247</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2002 Jan 1;20(1):289-96</RefSource>
<PMID Version="1">11773181</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2007 Dec 22;370(9605):2103-11</RefSource>
<PMID Version="1">18156031</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2012 Sep 20;30(27):3402-7</RefSource>
<PMID Version="1">22891270</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur Urol. 2012 Feb;61(2):307-16</RefSource>
<PMID Version="1">22055147</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2008 Aug 9;372(9637):449-56</RefSource>
<PMID Version="1">18653228</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2008 Nov 20;26(33):5422-8</RefSource>
<PMID Version="1">18936475</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2010 Feb 20;28(6):1061-8</RefSource>
<PMID Version="1">20100962</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer. 2010 Dec 1;116(23 ):5383-90</RefSource>
<PMID Version="1">20806321</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>World J Urol. 2013 Aug;31(4):805-9</RefSource>
<PMID Version="1">21512806</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2009 Aug 1;27(22):3584-90</RefSource>
<PMID Version="1">19487381</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2011 Jan;22(1):145-8</RefSource>
<PMID Version="1">20595449</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020533" MajorTopicYN="N">Angiogenesis Inhibitors</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002292" MajorTopicYN="N">Carcinoma, Renal Cell</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
<QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007680" MajorTopicYN="N">Kidney Neoplasms</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009536" MajorTopicYN="N">Niacinamide</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010671" MajorTopicYN="N">Phenylurea Compounds</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011758" MajorTopicYN="N">Pyrroles</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D040262" MajorTopicYN="N">Receptors, Vascular Endothelial Growth Factor</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year>
<Month>12</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2013</Year>
<Month>12</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2014</Year>
<Month>5</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">24297950</ArticleId>
<ArticleId IdType="pii">JCO.2013.50.3961</ArticleId>
<ArticleId IdType="doi">10.1200/JCO.2013.50.3961</ArticleId>
<ArticleId IdType="pmc">PMC5569683</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>État de New York</li>
</region>
</list>
<tree><noCountry><name sortKey="Bjarnason, Georg A" sort="Bjarnason, Georg A" uniqKey="Bjarnason G" first="Georg A" last="Bjarnason">Georg A. Bjarnason</name>
<name sortKey="Escudier, Bernard" sort="Escudier, Bernard" uniqKey="Escudier B" first="Bernard" last="Escudier">Bernard Escudier</name>
<name sortKey="Esteban, Emilio" sort="Esteban, Emilio" uniqKey="Esteban E" first="Emilio" last="Esteban">Emilio Esteban</name>
<name sortKey="Hariharan, Subramanian" sort="Hariharan, Subramanian" uniqKey="Hariharan S" first="Subramanian" last="Hariharan">Subramanian Hariharan</name>
<name sortKey="Lim, Ho Yeong" sort="Lim, Ho Yeong" uniqKey="Lim H" first="Ho Yeong" last="Lim">Ho Yeong Lim</name>
<name sortKey="Lu, Dongrui Ray" sort="Lu, Dongrui Ray" uniqKey="Lu D" first="Dongrui Ray" last="Lu">Dongrui Ray Lu</name>
<name sortKey="Motzer, Robert J" sort="Motzer, Robert J" uniqKey="Motzer R" first="Robert J" last="Motzer">Robert J. Motzer</name>
<name sortKey="Niethammer, Andreas" sort="Niethammer, Andreas" uniqKey="Niethammer A" first="Andreas" last="Niethammer">Andreas Niethammer</name>
<name sortKey="Pittman, Kenneth B" sort="Pittman, Kenneth B" uniqKey="Pittman K" first="Kenneth B" last="Pittman">Kenneth B. Pittman</name>
<name sortKey="Senico, Peggy" sort="Senico, Peggy" uniqKey="Senico P" first="Peggy" last="Senico">Peggy Senico</name>
</noCountry>
<country name="États-Unis"><region name="État de New York"><name sortKey="Hutson, Thomas E" sort="Hutson, Thomas E" uniqKey="Hutson T" first="Thomas E" last="Hutson">Thomas E. Hutson</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003253 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 003253 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= PubMed |étape= Checkpoint |type= RBID |clé= pubmed:24297950 |texte= Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:24297950" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a AustralieFrV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |